Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Lakewood-Amedex Biotherapeutics / Equity Bottom-Up

Lakewood-Amedex Biotherapeutics (LABT US)

<ul><li>On September 24, 2026, Lakewood-Amedex Biotherapeutics, Inc. (LABT) announced that the first patient has been dosed in the Phase 2a clinical trial of Nu-3 for the treatment of diabetic foot ulcers.</li><li>It is.</li><li>Multicenter, single blind, dose-finding study designed to evaluate the safety and efficacy of three Nu-3 gel concentrations (2%, 5%, and 10%).</li></ul>

On September 24, 2026, Lakewood-Amedex Biotherapeutics, Inc. (LABT) announced that the first patient has been dosed in the Phase 2a clinical trial of Nu-3 for the treatment of diabetic foot ulcers.It is.Multicenter, single blind, dose-finding study designed to evaluate the safety and efficacy of three Nu-3 gel concentrations (2%, 5%, and 10%).

LABT:  First Patient Dosed in Phase 2a Trial of Nu-3 for Infected Diabetic Foot Ulcers